452095-63-5

Upstream product

• 620-24-6 3-Hydroxybenzyl alcohol 
• 66074-00-8 3,4-bis(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 

Downstream Products

• 1538580-62-9 (Z)-4-(3-((2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
• 1538580-71-0 (Z)-4-(3-((2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
• 1538580-53-8 (Z)-4-(3-((2-(5-fluoro-2-methyl-1-(4-(methylsulfinyl)benzylidene)-1H-inden-3-yl)acetoxy)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
• 1043914-09-5 3-({4-[(3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy}benzyl)oxy]-4-oxobutanoyl}oxy)olean-12-en-28-oic acid 
• 1043914-13-1 28-(benzyloxy)-28-oxoolean-12-en-3-yl 3-{[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy}benzyl succinate 

Relevant academic research and scientific papers

Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor

On the basis of the strategy of creating multifunctional drugs, a novel series of phenylsulfonylfuroxan-based hydroxamates with histone deacetylase (HDAC) inhibitory and nitric oxide (NO) donating activities were designed, synthesized, and evaluated. The

A 1, 2, 5-oxadiazol-2-oxide histone deacetylase inhibitors and its preparation method and application

The invention relates to an l,2,5-oxadiazole-2-oxide histone deacetylase inhibitor as well as a preparation method and an application thereof. The compound has a structure as shown in formula I. The compound provided by the invention is used for preparing

Synthesis and biological evaluation of nitric oxide-donating analogues of sulindac for prostate cancer treatment

A series of analogues of the non-steroidal anti-inflammatory drug (NSAID) sulindac 1 were synthesised tethered to nitric oxide (NO) donating functional groups. Sulindac shows antiproliterative effects against immortal PC3 cell lines. It was previously demonstrated that the effect can be enhanced when tethered to NO releasing groups such as nitrate esters, furoxans and sydnonimines. To explore this approach further, a total of fifty-six sulindac-NO analogues were prepared and they were evaluated as NO-releasing cytotoxic agents against prostate cancer (PCa) cell lines. Compounds 1k and 1n exhibited significant cytotoxic with IC50 values of 6.1 ± 4.1 and 12.1 ± 3.2 μM, respectively, coupled with observed nitric oxide release.